Clinical trials
Fever trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Catholic University of the Sacred Heart | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2 |
| Novartis Pharmaceuticals | 2 |
| A.O.U. Città della Salute e della Scienza | 1 |
| Amgen | 1 |
| Eli Lilly and Company | 1 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1 |
| Helsinki University Central Hospital | 1 |
| Istituto Ortopedico Rizzoli | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fever | 19 |
| Neutropenia | 4 |
| Blast Crisis | 2 |
| Burkitt Lymphoma | 2 |
| Hodgkin Disease | 2 |
| Hot Flashes | 2 |
| Immunoblastic Lymphadenopathy | 2 |
| Immunoglobulin Light-chain Amyloidosis | 2 |
| Infections | 2 |
| Intraocular Lymphoma | 2 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.